Outlining Advances Made in Ovarian Cancer in Oklahoma City
We traveled to Oklahoma City, Oklahoma, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the Stephenson Cancer Center faculty.
Related Articles
Fulzerasib Approved in China for KRAS G12C–Mutant Advanced NSCLC
China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.
Olaparib Monotherapy Elicits Responses in HRR+ Prostate Cancer With High-Risk Biochemical Recurrence
Olaparib produced responses in high-risk, biochemically recurrent prostate cancer with HRR alterations, particularly BRCA2 alterations.
FDA Grants Fast Track Designation to Neoadjuvant APG-157 for Head and Neck Cancer
The FDA has granted fast track designation to APG-157 for the neoadjuvant treatment of head and neck cancer.
DSP-5336 Is Safe, Generates Responses in KMT2A+ or NPM1+ R/R AML
Naval G. Daver, MD, discusses efficacy and safety data from the first-in-human phase 1/2 study investigating DSP-5336 for relapsed or refractory acute leukemia.
EU Greenlights Odronextamab for R/R Follicular Lymphoma and DLBCL
The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.
Frontline Amivantamab/Lazertinib Combo Shows Trend of OS Benefit in Advanced EGFR+ NSCLC
When compared with osimertinib, amivantamab plus lazertinib showed a trend toward favorable overall survival in patients with EGFR-mutant advanced NSCLC.
FDA Grants Fast Track Designation to BGB-16673 in Previously Treated CLL/SLL
BGB-16673 has received FDA fast track designation for relapsed or refractory CLL or SLL following 2 or more prior lines of therapy.
PARP Inhibitors and ADCs Spark Change Across Ovarian and Cervical Cancer Paradigms
Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look…
CDK4/6 Inhibitors, ADCs, and PI3K Inhibitors Individualize HR+ Breast Cancer Management
Shipra Gandhi, MD, discusses the evolution of CDK4/6 inhibitors and ADCs across breast cancer subtypes.
TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC
An exploratory analysis from the TROPION-Lung 01 study shows that positivity for TROP2 normalized membrane ratio can be predictive for improved efficacy in patients with…